Aurisco Pharmaceutical Co (SHSE:605116) 9-Day RSI: 62.94 (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605116 Aurisco Pharmaceutical Co Ltd SHSE:605116
77 GF Score
Price ¥20.70
GF Value ¥28.54
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aurisco Pharmaceutical Co 9-Day RSI?

Aurisco Pharmaceutical Co SHSE:605116 +0.83% 77 9-Day RSI is 62.94 as of Aug. 12, 2026. GuruFocus rates SHSE:605116 with a GF Score™ of 77/100 and a GF Value™ of ¥28.54 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Aurisco Pharmaceutical Co ranks worse than 65.68% on this metric.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-08-12), Aurisco Pharmaceutical Co's 9-Day RSI is 62.94.

The industry rank for Aurisco Pharmaceutical Co's 9-Day RSI or its related term are showing as below:

SHSE:605116's 9-Day RSI is ranked worse than
65.68% of 1416 companies
in the Biotechnology industry
Industry Median: 54.885 vs SHSE:605116: 62.94

Aurisco Pharmaceutical Co  (SHSE:605116) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Aurisco Pharmaceutical Co 9-Day RSI Related Terms


SHSE:605116 vs VRTX, REGN, RVMD: 9-Day RSI Comparison

For the Biotechnology subindustry, Aurisco Pharmaceutical Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurisco Pharmaceutical Co 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Aurisco Pharmaceutical Co's 9-Day RSI falls into.


SHSE:605116
77GF Score
Aurisco Pharmaceutical Co Ltd SHSE:605116
9-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurisco Pharmaceutical Co  (SHSE:605116) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 9-Day RSI →
What does a 9-Day RSI of 62.94 mean?
Aurisco Pharmaceutical Co (SHSE:605116) has a 9-Day RSI of 62.94 as of Aug. 12, 2026. According to the industry distribution chart, Aurisco Pharmaceutical Co ranks #930 out of 1416 companies in the Biotechnology industry, placing it in the top 65.7%.
Is Aurisco Pharmaceutical Co's 9-Day RSI too high?
Aurisco Pharmaceutical Co's current 9-Day RSI is 62.94. The Biotechnology industry median 9-Day RSI is 54.89. Aurisco Pharmaceutical Co's value of 62.94 is 14.7% above this industry median. Based on the distribution chart, Aurisco Pharmaceutical Co ranks #930 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aurisco Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurisco Pharmaceutical Co's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aurisco Pharmaceutical Co ranks #930 out of 1416 companies for 9-Day RSI. This places Aurisco Pharmaceutical Co in the lower half of its industry. The industry median 9-Day RSI is 54.89. Aurisco Pharmaceutical Co's value of 62.94 is 14.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 54.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurisco Pharmaceutical Co's current 9-Day RSI of 62.94 is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 54.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurisco Pharmaceutical Co's current 9-Day RSI is 62.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurisco Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co (SHSE:605116) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.54, compared to a current price of ¥20.70 — trading 27.5% below its estimated fair value. The current 9-Day RSI is 62.94 and 14.7% above the Biotechnology industry median of 54.89. Aurisco Pharmaceutical Co's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Aurisco Pharmaceutical Co (SHSE:605116), the current 9-Day RSI is 62.94 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurisco Pharmaceutical Co (SHSE:605116) Overvalued in 2026?

Based on GuruFocus' analysis, Aurisco Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥20.70 is trading 27.5% below its estimated GF Value™ of ¥28.54. GuruFocus considers Aurisco Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:605116:

  • 9-Day RSI: 62.94
  • GF Value™: ¥28.54 vs. price of ¥20.70 (27.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs
  • Industry Position: 14.7% above the Biotechnology median (#930 of 1416)

No single metric tells the full story. See the SHSE:605116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurisco Pharmaceutical Co Business Description

Address Badu Industrial Park, Tiantai County, Zhejiang Province, Taizhou, CHN, 317200
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
77GF Score

Get the complete analysis for SHSE:605116

9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥20.70
Price
¥28.54
GF Value